3 active not recruiting, 3 recruiting, 2 completed, 1 not yet recruiting. 5 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Active not recruiting 2, Recruiting 2, Not yet recruiting 1 |
| Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Lung Neuroendocrine Neoplasm: new trials by email Literature Review of Lung Neuroendocrine Neoplasm trials Research Report on Lung Neuroendocrine Neoplasm
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas Biospecimen Collection, Computed Tomography, Incomplete Freund''s Adjuvant - Digestive System Neuroendocrine Neoplasm, Lung Neuroendocrine Neoplasm | Phase 2 | Not yet recruiting | Roswell Park Cancer Institute | 60 | 2026-12-15 | 2026-10-20 |
| Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus. 177Lu-edotreotide, Everolimus - Neuroendocrine Tumors, Lung Neuroendocrine Neoplasm | Phase 3 | Recruiting | Grupo Espanol de Tumores Neuroendocrinos | 170 | 2023-10-27 | 2026-05-12 |
| Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors Biospecimen Collection, Computed Tomography, Everolimus - Advanced Lung Neuroendocrine Tumor, Functioning Lung Neuroendocrine Tumor | Phase 2 | Recruiting | National Cancer Institute (NCI) | 70 | 2023-02-03 | 2026-10-19 |
| Neuroendocrine Tumors - Patient Reported Outcomes Neuroendocrine Tumors, Gastroenteropancreatic Neuroendocrine Tumor | Active not recruiting | University of Iowa | 2539 | 2022-05-10 | 2026-08-20 | |
| A Trial Evaluating the Activity and Safety of Combination Between Cabozantinib and Temozolomide in Lung and GEP-NENS Progressive After Everolimus, Sunitinib or PRRT (CABOTEM) Cabozantinib and Temozolomide - Lung Neuroendocrine Neoplasm, GEP Neuroendocrine Tumor | Phase 2 | Recruiting | National Cancer Institute, Naples | 35 | 2021-06-15 | 2024-06-18 |
| Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors CVM-1118 - Neuroendocrine Tumors, Pancreatic Neuroendocrine Tumor | Phase 2 | Active not recruiting | TaiRx, Inc. | 34 | 2018-12-15 | 2025-12-23 |
| Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung Cancer Nivolumab, Stereotactic Body Radiation Therapy - Lung Atypical Carcinoid Tumor, Lung Neuroendocrine Neoplasm | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 140 | 2017-06-26 | 2026-06-22 |
| Clinical Utility Assay as a Biomarker for Gastroenteropancreatic and Lung Neuroendocrine Tumors NETest - Gastroenteropancreatic Neuroendocrine Tumor, Lung Neuroendocrine Neoplasm | Completed | H. Lee Moffitt Cancer Center and Research Institute | 105 | 2017-01-09 | 2021-08-04 | |
| Safety and Efficacy of RAD001 in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor RAD001 - Lung Neuroendocrine Neoplasm | Phase 1 | Completed | Novartis Pharmaceuticals | 16 | 2010-12-01 | 2014-12-30 |
Gastro-enteropancreatic neuroendocrine tumor (4) · Carcinoma, Neuroendocrine (3) · Neuroendocrine Tumors (3) · Adenoma, Islet Cell (2) · Lung Neoplasms (2) · Adenocarcinoma of Lung (1) · Adenocarcinoma, Bronchiolo-Alveolar (1) · Carcinoma, Non-Small-Cell Lung (1) · Neoplasms (1) · Pancreatic Neoplasms (1) · Thymus Neoplasms (1)
Neoplasms (5) · Neoplasms by Histologic Type (5) · Neoplasms by Site (5) · Neoplasms, Germ Cell and Embryonal (4) · Neoplasms, Glandular and Epithelial (4) · Neoplasms, Nerve Tissue (4) · Neuroectodermal Tumors (4) · Adenocarcinoma (3) · Carcinoma (3) · Digestive System Diseases (3) · Digestive System Neoplasms (3) · Endocrine Gland Neoplasms (3) · Endocrine System Diseases (3) · Pancreatic Diseases (3) · Thoracic Neoplasms (3)
Everolimus (3) · Magnetic Resonance Spectroscopy (2) · Specimen Handling (2) · Temozolomide (2) · 177Lu-octreotide, DOTA(0)-Tyr(3)- (1) · Colony-Stimulating Factors (1) · Fluorodeoxyglucose F18 (1) · Nivolumab (1) · Photons (1) · Radiosurgery (1) · X-Rays (1) · cabozantinib (1) · incomplete Freund's adjuvant (1) · lutetium Lu 177 dotatate (1) · montanide ISA 51 (1)
Grupo Espanol de Tumores Neuroendocrinos (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · M.D. Anderson Cancer Center (1) · National Cancer Institute (NCI) (1) · National Cancer Institute, Naples (1) · Novartis Pharmaceuticals (1) · Roswell Park Cancer Institute (1) · TaiRx, Inc. (1) · University of Iowa (1)
United States (5) · Italy (2) · Belgium (1) · China (1) · France (1) · Spain (1) · Taiwan (1)
Jasmeet Kaur, MD (1) · Jaume Capdevila, M.D. Ph.D. (1) · Joe Y Chang (1) · Jonathan Strosberg, M.D. (1) · Michael O'Rorke, PhD (1) · Thomas A Hope (1) · Wu-Chou Su (1)
PMID 37478883, PMID 40186126, PMID 41963331, PMID 42043735, PMID 42393461
U10CA180821 (1)